MedTrace Logo

4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

NCT01139151 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2014-06-17

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of 4'-thio-araC (thiarabine) that can be given to patients with advanced blood cancer. The safety of this drug will also be studied and 2 different dose schedules will be tested.

Conditions

Interventions

DRUG

3 Day Thiarabine

Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3

DRUG

5 Day Thiarabine

Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5

Sponsors & Collaborators

  • Access Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Hagop Kantarjian, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01139151 on ClinicalTrials.gov